AU2021365153A1 - Transcription active complex targeting cancer drug from viral protein sequence - Google Patents

Transcription active complex targeting cancer drug from viral protein sequence Download PDF

Info

Publication number
AU2021365153A1
AU2021365153A1 AU2021365153A AU2021365153A AU2021365153A1 AU 2021365153 A1 AU2021365153 A1 AU 2021365153A1 AU 2021365153 A AU2021365153 A AU 2021365153A AU 2021365153 A AU2021365153 A AU 2021365153A AU 2021365153 A1 AU2021365153 A1 AU 2021365153A1
Authority
AU
Australia
Prior art keywords
peptide
cell
polypeptide
myc
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021365153A
Other languages
English (en)
Other versions
AU2021365153A9 (en
Inventor
Yoshihiro IZUMIYA
Michiko SHIMODA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2021365153A1 publication Critical patent/AU2021365153A1/en
Publication of AU2021365153A9 publication Critical patent/AU2021365153A9/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C12N2710/16422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16411—Rhadinovirus, e.g. human herpesvirus 8
    • C12N2710/16433—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2021365153A 2020-10-21 2021-10-21 Transcription active complex targeting cancer drug from viral protein sequence Pending AU2021365153A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063094766P 2020-10-21 2020-10-21
US63/094,766 2020-10-21
US202163152959P 2021-02-24 2021-02-24
US63/152,959 2021-02-24
US202163222697P 2021-07-16 2021-07-16
US63/222,697 2021-07-16
PCT/US2021/055979 WO2022087221A1 (en) 2020-10-21 2021-10-21 Transcription active complex targeting cancer drug from viral protein sequence

Publications (2)

Publication Number Publication Date
AU2021365153A1 true AU2021365153A1 (en) 2023-05-25
AU2021365153A9 AU2021365153A9 (en) 2024-10-24

Family

ID=81290054

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021365153A Pending AU2021365153A1 (en) 2020-10-21 2021-10-21 Transcription active complex targeting cancer drug from viral protein sequence

Country Status (7)

Country Link
US (1) US12528840B2 (https=)
EP (1) EP4232061A4 (https=)
JP (1) JP2023549476A (https=)
KR (1) KR20230092938A (https=)
AU (1) AU2021365153A1 (https=)
CA (1) CA3195795A1 (https=)
WO (1) WO2022087221A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4616864A1 (en) * 2024-03-11 2025-09-17 Peptomyc, S.L. Compound for the treatment of autoimmune diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060263382A1 (en) * 1998-06-20 2006-11-23 Richard Hotchkiss Membrane-permeant peptide complexes for treatment of sepsis
WO2014127148A1 (en) 2013-02-14 2014-08-21 The J. David Gladstone Institutes Compositions and methods of use thereof for identifying anti-viral agents
WO2019108134A1 (en) 2017-11-29 2019-06-06 Agency For Science, Technology And Research Chimeric molecule for targeting c-myc in cells

Also Published As

Publication number Publication date
JP2023549476A (ja) 2023-11-27
CA3195795A1 (en) 2022-04-28
US12528840B2 (en) 2026-01-20
EP4232061A4 (en) 2024-10-16
AU2021365153A9 (en) 2024-10-24
EP4232061A1 (en) 2023-08-30
KR20230092938A (ko) 2023-06-26
WO2022087221A1 (en) 2022-04-28
US20230382953A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
US10973917B2 (en) MRNA combination therapy for the treatment of cancer
JP7064234B2 (ja) Ｓｉｒｐポリペプチド組成物および使用の方法
JP2021167353A (ja) 自己免疫疾患およびがんを処置するための組成物および方法
US20180010114A1 (en) Combination cancer immunotherapies with arginine depletion agents
JP7289029B2 (ja) 分子誘導システムペプチド及びその使用
AU2021328359B2 (en) Modified porcine pancreatic elastase proteins
JP7525408B2 (ja) ペプチドを用いる併用療法
US20250064889A1 (en) Trpv6 inhibitors and combination therapies for treating cancers
US12528840B2 (en) Transcription active complex targeting cancer drug from viral protein sequence
JP2026026192A (ja) Ｐｌａ２ｇ２ｄアンタゴニストによる癌またはウイルス感染を処置するための方法および組成物
WO2014098319A1 (ko) T 세포 특이적인 인간화 단일조각항체 전달체
WO2022187583A1 (en) Combination therapies with tim-3-based chimeric proteins
EP4301470A1 (en) Combination therapies with sirp alpha-based chimeric proteins
CN116917337A (zh) 来自病毒蛋白序列的转录活性复合物靶向癌症药物
CN118201953A (zh) 新型干扰素变体及其双功能融合分子
US20160082104A1 (en) Methods and Compositions for the Treatment of Proliferative and Pathogenic Diseases
TW202328176A (zh) 抗-sars-cov-2抗體組成物及其用途
WO2010081787A1 (en) IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS
CN117192118B (zh) 一种抗cldn 18.2和cd47的双特异性抗体治疗疾病的用途
EP4538285A1 (en) Pd-1 variant and use thereof
JP2025503924A (ja) 抗ｂ７－ｈ３化合物及び使用方法
JP2026513892A (ja) タンパク質複合体を含む医薬組成物
HK40093016A (zh) 经修饰的猪胰腺弹性蛋白酶蛋白

Legal Events

Date Code Title Description
SREP Specification republished